Funding

Psychedelic biotech startup Psylo raises $5 million Seed round

- October 27, 2022 2 MIN READ

Psylo, a preclinical biotech firm, has raised $5 million in Seed funding as it looks to treat mental illness with naturally occurring psychedelic drugs. The fresh capital comes 12 months after the Sydney-based startup emerged Startmate‘s winter 21 cohort with an initial $1.1 million in capital from the likes Airtree’s Daniel Petre in a round led led… Read more »

Funding

Psychedelic biotech startup Psylo raises $1.1m to treat mental health issues with the key ingredient in magic mushrooms

- October 1, 2021 2 MIN READ

Psylo, a preclinical biotech firm, has raised $1.1 million as part of an ambitious plan to treat mental illness with naturally occurring psychedelic drugs. The Sydney-based startup, part of Startmate‘s current W21 cohort, has been backed in a round led led by Chris Hitchen’s global micro-VC fund Possible Ventures. The venture’s prominent angel investors also include Airtree’s… Read more »